Evidence map›Paper›PMID 39083107›Full record

ArticleWorld journal of microbiology & biotechnology2024

Inhibitory effect of Jingfang mixture on Staphylococcus aureus α-hemolysin.

Wenting Ni, Hongguang Tang, Chenghong Sun, Jingchun Yao, Xiaoping Zhang, Guimin Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of microbiology & biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenting Ni *College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250300, China.
Hongguang Tang *College of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Chenghong SunState Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 273400, China.
Jingchun YaoState Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co. LTD., Linyi, 273400, China.
Xiaoping ZhangCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250300, China. xia_opingzhang@126.com.
Guimin ZhangCollege of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250300, China. lunanzhangguimin@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staphylococcus aureus is a gram-positive bacteria, and its virulence factors can cause many kinds of infections, such as pneumonia, sepsis, enteritis and osteomyelitis. Traditional antibiotics can not only kill bacteria, but also easily lead to bacterial resistance. Jingfang Mixture (JFM) has the effects of inducing sweating and relieving the exterior, dispelling wind and eliminating dampness, and is commonly used in clinic to prevent and treat epidemic diseases and infectious diseases. The main purpose of this study is to explore the inhibitory effect of JFM on alpha-hemolysin (Hla) of S. aureus and to alleviate the damage caused by Hla. We found that JFM could inhibit the hemolytic activity, transcription level and neutralizing activity of Hla in a dose-dependent manner at the concentrations of 125, 250 and 500 µg/mL, without affecting the growth of bacteria. In addition, JFM reduced the damage of Hla to A549 cells and the release of lactate dehydrogenase (LDH). We also observed that in the S. aureus - induced pneumonia mouse model, JFM could significantly prolong the life of mice, reduce the bacterial load in the lungs, significantly improve the pathological state of the lungs and alleviate the damage caused by inflammatory factors, and the pathogenicity of gene deletion strain DU 1090 of S. aureus to pneumonia mice was also significantly reduced. In conclusion, this study proved that JFM is a potential drug against S. aureus infection, and this study provided a preliminary study for better guidance of clinical drug use.

Indexed as

Anti-Bacterial AgentsHemolysin ProteinsStaphylococcal InfectionsStaphylococcus aureusA549 CellsAnimalsBacterial LoadBacterial ToxinsDisease Models, AnimalDrugs, Chinese HerbalFemaleHemolysisHumansLungMiceMice, Inbred BALB CAnti-Bacterial AgentsBacterial ToxinsDrugs, Chinese HerbalHemolysin Proteinsstaphylococcal alpha-toxinVirulence FactorsAnti-virulence strategyDU 1090Jingfang mixtureStaphylococcus aureusΑ-hemolysin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.